year left
relev valu convert eur usd
ag fse vsc clinic stage biopharma compani primarili focus
develop oncolog treatment epigenet cancer driver well
immunotherapi combin compani lead clinic candid resminostat pan-
hdac inhibitor develop first mainten therapi patient cutan
cell lymphoma registr phase ii trial on-going top-line data expect
domatinostat select class hdac inhibitor initi
develop combin inhibitor melanoma gastrointestin cancer
potenti registr trial merkel cell carcinoma begin also
addit preclin out-licens preclin clinic candid could provid
addit upsid futur
point discuss
resminostat pan-hdac inhibitor ration develop ctcl
resminostat oral administ pan-histon deacetylas hdac inhibitor
modul gene express epigenet level evalu registr
direct phase ii resmain trial mainten therapi cutan cell lymphoma
ctcl activ hdac inhibit ctcl valid approv
zolina vorinostat merck nyse istodax romidepsin celgen
celg current mainten therapi approv
diseas notabl treatment resminostat abl reduc express
often associ pain common itch cessat ctcl patient often
experi phase ii studi also recent initi japan partner yakult honsha
tyo evalu resminostat plu chemotherapi second-lin biliari tract
cancer btc top-line data studi expect
begin phase ii trial domatinostat bavencio gi tumor
initi phase ib/ii data domatinostat keytruda melanoma
first patient recruit phase ii trial resminostat ctcl
safeti data phase ii studi domatinostat bavencio gi tumor
public mcc preclin data domatinostat
complet phase ib/ii studi domatinostat keytruda melanoma
initi pivot mcc studi domatinostat inhibitor
top-line data registr phase ii studi resminostat ctcl
data phase ii studi domatinostat bavencio gi tumor
potenti file resminostat ctcl
top-line data phase ii studi resminostat line biliari tract
analyst certif disclosur pleas see page
domatinostat develop combin partner inhibitor domatinostat
oral administ select class hdac inhibitor primarili develop combin treatment
inhibitor conduct phase ib/ii studi test domatinostat plu merck nyse keytruda
pembrolizumab melanoma patient progress inhibitor alon preliminari data
expect studi complet investig sponsor phase ii
emerg trial plan begin test domatinostat pfizer/merck kgaa nyse pfe/etr pd-
inhibitor bavencio avelumab chemotherapi experienc checkpoint nave patient advanc stage micro-
satellit stabl gastrointestin cancer depend data two studi plan begin pivot trial
domatinostat patient relapsed/refractori advanc merkel-cel carcinoma
rational combin class hdac inhibit class hdac inhibit may induc sever
posit chang tumor microenviron enhanc activ checkpoint inhibitor preclin studi
domatinostat demonstr abil increas number cell stimul natur killer cell activ
enhanc inflammatori signatur increas present tumor associ antigen class hdac
inhibit also associ increas mhc/hla express increas suscept
cancer cell immun attack follow inhibit combin domatinostat inhibit
result addit effect mice support clinic develop
preclin out-licens candid provid addit revenu opportun
preclin develop inhibitor two kinas requir hedgehog/gli signal hedgehog pathway
inhibitor erivedg vismodegib genentech vtx rog vx odomzo sonidegib sun pharma nse
sunpharma fda approv patient advanc basal cell carcinoma target hedgehog
signal upstream gli transcript factor howev cancer stem cell propos hedgehog
signal typic activ downstream gli level provid potenti point differenti
phase i/ii studi anticip begin
strive optim valu non-cor asset licens deal pharmaceut biotech compani
current non-cor drug candid out-licens compani includ guangzhou
lingsheng pharma co privat immun ag privat maruho privat panopt pharma privat
privat term deal could elig futur non-dilut mileston payment
trade frankfurt stock exchang current million ordinari share outstand
april compani provid financi result first quarter monthli use cash
oper million quarter compar million period
increas oper cost primarili driven on-going clinic trial march compani cash
cash equival million expect fund oper
tabl content
clinic data discuss resminostat
registr direct resmain studi ctcl
market inform non-respond
domatinostat metastat melanoma
market inform melanoma patient respond inhibitor
domatinostat gastrointestin tumor
domatinostat merkel cell carcinoma
clinic data discuss domatinostat
prior phase studi advanc hematolog malign
phase ib/ii sensit studi melanoma patient progress therapi
competit landscap immuno-oncolog drug develop
risk invest
ag fse vsc german base clinic stage biopharma compani primarili focus develop
oncolog treatment epigenet cancer driver well immunotherapi combin compani lead
clinic candid resminostat oral administ pan-hdac inhibitor modul gene express
epigenet level preclin studi suggest drug enhanc immun respons cancer
inhibit tumor cell progress metastat phenotyp re-sensit cell becom resist standard
medic resminostat previous evalu treatment hepatocellular carcinoma
hodgkin lymphoma hl colorect cancer non-smal cell lung cancer nsclc among indic
current development focu mainten therapi patient cutan cell lymphoma ctcl
registr phase ii trial on-going phase ii studi also recent initi japan partner yakult
honsha tyo evalu resminostat plu chemotherapi second-lin biliari tract cancer btc
top-line data studi expect respect yakult honsha tyo
exclus licens develop resminostat japan compani development pipelin illustr
note compani out-licens program list
domatinostat oral administ small molecul select class histon deacetylas
hdac inhibitor develop combin treatment inhibitor inhibit hdac class
may induc sever posit chang tumor microenviron enhanc activ checkpoint inhibitor
preclin studi domatinostat demonstr abil increas number cell stimul
natur killer cell activ enhanc inflammatori signatur increas present tumor associ
class hdac inhibit also shown abil up-regul mhc/hla express
increas suscept cancer cell inhibit
conduct phase ib/ii studi test combin domatinostat merck nyse keytruda
pembrolizumab melanoma patient progress inhibitor alon initi data readout
expect studi complet addit investig sponsor phase ii
emerg trial plan begin test domatinostat pfizer/merck kgaa nyse pfe/etr
inhibitor bavencio avelumab chemotherapi experienc checkpoint inhibitor nave patient
advanc stage micro-satellit stabl gastrointestin cancer typic respond checkpoint inhibitor
depend data two studi plan begin pivot trial domatinostat
refractori merkel-cel carcinoma addit test candid preclin studi call
inhibit two kinas requir hedgehog/gli signal
compani strive optim valu non-cor asset licens deal pharmaceut biotech
compani current non-cor drug candid out-licens compani includ
privat privat term deal could elig futur non-dilut
resminostat oral administ pan-histon deacetylas hdac inhibitor modul gene express
epigenet level preclin studi shown drug select class iib iv hdac enzym
increas specif toward studi suggest drug increas nk cell activ
enhanc immun respons cancer inhibit tumor cell progress metastat phenotyp re-sensit
cell becom resist specif medic resminostat previous evalu hepatocellular
carcinoma hodgkin lymphoma hl colorect cancer non-smal cell lung cancer nsclc
among indic result show treatment well toler cancer drug antitumor activ
observ current develop focus registr direct phase ii resmain trial mainten
therapi cutan cell lymphoma ctcl phase ii studi also also recent initi japan partner
yakult honsha tyo evalu resminostat plu chemotherapi second-lin biliari tract cancer btc
top-line data studi expect respect yakult honsha tyo
exclus licens develop resminostat japan term collabor receiv
up-front payment million elig million mileston plu double-digit royalti
potenti sale molecular structur resminostat shown figur
kohlhof et al epigenet modul pave way checkpoint inhibit journal clinic oncolog
figur molecular structur resminostat
notabl receiv pediatr investig waiver ema resminostat advanced-stag
ctcl mean on-going resmain studi could also support approv pediatr ctcl
knowledg resminostat treatment develop mainten therapi diseas
treatment develop diseas studi earli late stage set
hdac background histon deacetylas hdac consist famili protein divid follow four
group class hdac class ii hdac class sirtuin class iv hdac
hdac histon acetyl transferas hat help regul gene express remov ad acetyl group
histon non-histon lysin sever form cancer histon lysin acetyl becom dysregul
upregul hdac activ hat result activ silenc gene
contribut cancer format progress hdac inhibit could restor acetyl
potenti revers cancer current hdac inhibitor approv us
hematolog malign although select class inhibitor like domatinostat effect differ
cell type anti-cancer effect seen hdac inhibit includ interf cell turnov decreas cell motil
angiogen increas cell death howev note effect inhibit hdac class
differ
resminostat inhibit growth ctcl cell transcript factor belong
stat protein famili mediat sever aspect immun prolifer apoptosi differenti
necessari develop helper th cell loss express ctcl implic
marker contrari found upregul ctcl associ
phenotyp suppress respons enforc bia
akimova histone/protein deacetylas t-cell immun respons blood
kroesen et al hdac inhibitor immunotherapi doubl edg sword oncotarget
reddi romidepsin treatment relapsed/refractori cutan t-cell lymphoma mycosi fungoides/sezari
syndrom use commun set critic review oncology/hematolog
litvinov et al analysi express cutan t-cell lymphoma ctcl patient patient-deriv
guenova et al cytokin malign cell suppress respons enforc global bia leukem
vitro studi found addit suppress growth ctcl cell line resminostat caus increas
concomit decreas shown top panel figur suggest
drug might inhibit diseas progress stabil cell popul skin lesion experi
hh cell treat resminostat vari concentr stat express
measur qpcr hour moreov result shown bottom panel figur support drug
epigenet mode action chromatin immunoprecipit analysi employ analyz acetyl state
histon promot show dose depend increas acetyl
figur resminostat effect stat stat
resminostat downregul express itch mediat key characterist ctcl pain
common itch cessat one itch mediat cytokin commonli found ctcl
lower result improv resminostat effect express test cell line use
rna-seq qpcr shown figur treatment led dose depend reduct rna express
indic resminostat could improv itch symptom commonli experienc ctcl data
consist use hdac inhibitor
wulff et al resminostat epigenet approach ctcl mainten treatment clinic epigenet intern
cedeno-laur et al improv pruritu correl lower level ctcl patient differ
therapeut modal journal clinic immunolog
resminostat regul gene express dose-depend manner
major differenti regul gene up-regul
itch mediat target gene resminostat
resminostat reduc express relat itch ctcl
resminostat promis drug ctcl therapi
valid target gene resminostat
left rna-seq result normal rna express shown fold chang fc control ctrl dmso
valid qpcr rna express shown fold chang fc control ctrl dmso express
level normal housekeep gene actb
right chip-qpcr analysi transcript start site tss enrich shown input
compar non-specif igg control
natur killer nk cell activ resminostat resminostat may also play broader role activ
cellular immun cancer preclin studi shown tumor cell treat drug enhanc
nk mediat cell lysi shown top left panel figur mechan behind effect still unclear
data support sensit tumor cell direct activ nk cell
pretreat sever tumor cell line also result dose depend increas ligand shown
result genome-wid vitro studi resminostat ctcl
bottom left portion figur express nk cell activ bind ligand
target cell result lysi target cell pretreat nk cell resminostat caus increas
effect translat genome-wid dose-depend manner
express marker nk cell activ enhanc cytolyt activ mechan may import
genome-wid increas histon acetyl level
pretreat target effector cell result highest level nk mediat cell death depict
signific modul gene express
bottom right portion figur
regul gene induct repress
modul immun stress respons adhesion-rel pathway
switch unfavor favor gene express
regul advanc activ diseas marker
repress itching-rel factor
data support clinic develop resminostat
ctcl mainten set resmain studi
rna-seq differenti express analysi ctcl cell line my-la resminostat treatment
my-la cell incub resminostat dmso control rna express
analys rna-seq differenti express evalu adj adjust p-valu
differenti express gene deg filter fold chang adjust p-valu
deg analys pathway enrich metascap cluster top-enrich pathway illustr ptm post-
emtherapi project conduct framework
european eurostar program receiv fund
feder ministri educ research
figur effect resminostat nk cell
figur resminostat enhanc nk cell mediat cytolysi tumor cell top left enhanc nk lysi cell treatment resminostat
bottom left resminostat increas express ligand sever tumor cell type top-middl pretreat nk cell resminostat result
upregul enhanc cytolyt activ bottom right comparison cytolyt activ target effector pretreat
primarili focus develop resminostat mainten treatment cutan cell lymphoma
ctcl ctcl heterogen slow grow form non-hodgkin lymphoma affect cell usual
manifest inflam skin legion contain cell roughli peopl us eu diagnos
condit annual two main subtyp call mycosi fungoid szari syndrom make
combin two-third patient stage i-iia diseas good prognosi often live
patient stage iv diseas median os base retrospect analysi howev
surviv rate like improv due sever recent drug approv ctcl close patient
initi present early-stag diseas advanced-stag diseas time diagnosi ctcl often
wilcox cutan t-cell lymphoma updat diagnosi risk-stratif manag american
journal hematolog
wilcox cutan t-cell lymphoma updat diagnosi risk-stratif manag american
journal hematolog
 et al surviv outcom prognost factor mycosi fungoides/szari syndrom valid
revis intern societi cutan lymphomas/european organis research treatment cancer stage
propos journal clinic oncolog
misdiagnos benign skin condit incid may conserv increas better detect
method come market fact one studi found median time diagnosi year symptom
cancer includ rash-lik skin red dri skin enlarg lymph node sever itch significantli impact
qualiti life impair sleep patient also often experi skin infect due breakdown skin lesion
current curabl treatment ctcl patient progress cycl number topic
system therapi non-aggress natur diseas time progress patient qualiti
life import consid treatment option develop resminostat mainten therapi
patient ctcl achiev diseas control prior system therapi role hdac inhibit
treat ctcl valid approv zolina vorinostat merck nyse istodax
romidepsin celgen celg current mainten therapi approv
diseas discuss preclin portion report hdac inhibitor abl reduc
inflammatori cytokin play key role debilit itch symptom patient often experi addit
epigenet alter implic involv pathogenesi diseas support
use hdac thu mainten therapi resminostat potenti prevent recurr also
improv patient qualiti life shown figur resminostat could use variou potenti line
therapi possibl use cours diseas
resminostat ctcl mainten therapi
figur potenti applic resminostat mainten therapi ctcl
line treatment
treatment mention current cure ctcl goal treatment improv symptom
postpon progress use treatment toler profil early-stag ctcl patient typic
receiv skin-direct therapi manag dermatologist wherea advanced-stag diseas iib later typic
requir system therapi /- topic treatment overal evidence-bas stepwis algorithm place
andrew et al map transcriptom epigenom landscap hdac-inhibitor resist ctcl journal
immunolog
treat local diseas treatment consist topic corticosteroid topic chemotherapi
phototherapi local radiat topic imiquimod topic system therapi hdac inhibitor zolina
vorinostat istodax romidepsin approv istodax class specif hdac inhibitor approv
patient receiv least prior line system therapi overal respons rate orr istodax
patient popul experienc complet respons cr median durat respons achiev
patient month rang zolina pan-hdac inhibitor use patient
progress persist recurr diseas follow least system therapi approv base
orr open-label studi
recent adcetri brentuximab vedotin approv patient
primari cutan anaplast larg cell lymphoma pcalcl mf receiv prior
system therapi approv base result phase alcanza studi patient
experienc respons least month vs physician choic median
month adcentri treat patient vs month control arm addit mogamulizumab
mab develop kyowa hakko kirin tyo given prioriti review bla treat
ctcl patient receiv least prior system therapi phase mavor trial show
mogamulizumab reduc risk progress death compar zolina vorinostat pretreat
patient orr vs investigator-assess median month vs month
although clear evid effect ctcl patient also receiv allogen stem cell
uniqu posit develop resminostat mainten treatment patient ctcl
achiev diseas control prior system therapi current compet treatment approv
knowledg develop set thu resminostat could achiev consider market share
approv also note current hdac inhibitor approv ctcl europ
epidemiolog estim peopl diagnos us eu per year ctcl patient
ctcl progress avail therapi major late stage patient stage
i-iia diseas good prognosi often live patient stage iv diseas median
reddi romidepsin treatment relapsed/refractori cutan t-cell lymphoma mycosi
fungoides/sezari syndrom use commun set critic review oncology/hematolog
reddi romidepsin treatment relapsed/refractori cutan t-cell lymphoma mycosi
fungoides/sezari syndrom use commun set critic review oncology/hematolog
 et al surviv outcom prognost factor mycosi fungoides/szari syndrom valid
revis intern societi cutan lymphomas/european organ research treatment cancer stage
propos journal clinic oncolog
wilcox cutan t-cell lymphoma updat diagnosi risk-stratif manag american
journal hematolog
os base retrospect analysi howev surviv rate like improv due sever
recent drug approv ctcl develop resminostat use patient mf ss
achiev diseas control prior system therapi mf ss make roughli ctcl popul
posit data patient could lead broad approv resminostat ctcl base clinic trial result
approv agent late stage patient point diseas elig mainten therapi
clinic data discuss resminostat
resminostat studi patient date tumor type includ hepatocellular carcinoma
colorect cancer summari result select studi shown figur mention current
evalu resminostat registr direct phase ii resmain studi mainten treatment patient
ctcl achiev diseas control prior system therapi addit partner yakult honsha
tyo recent initi random double-blind placebo-control phase ii trial resminostat plu s-
chemotherapi second-lin biliari tract cancer japanes patient unresect recurr cancer
plan enrol primari endpoint trial result expect
 et al surviv outcom prognost factor mycosi fungoides/szari syndrom valid
revis intern societi cutan lymphomas/european organis research treatment cancer stage
propos journal clinic oncolog
evalu
progress
resminostat
dlt establish
mg daili
dlt establish
mg daili
day everi day combin
folfiri regimen
dlt establish
mg daili
escal
lower mpf mo orr
btc
regimen
btc
mg resminostat day
mg/day acc bsa
day
partner yakult honsha recent initi phase ii trial resminostat biliari tract cancer
resminostat toler cancer treatment monotherapi combin regimen
common associ therapi nausea vomit diarrhea fatigu thrombocytopenia
mild moder sever revers base mechanist clinic rational develop
resminostat ctcl focus develop mainten therapi
registr direct resmain studi ctcl
decemb initi registr direct phase ii resmain studi evalu resminostat
mainten treatment patient ctcl achiev diseas control prior system therapi
end novemb roughli one-third patient trial recruit
site open across european countri japan januari independ data safeti monitor board
evalu result first patient recommend studi continu without modif
protocol second data safeti monitor board review plan conduct patient enrol
top-lin result trial expect
phase ii trial design random double-blind placebo-control phase ii trial evalu resminostat
mainten treatment plan patient advanced-stag mycosi fungoid szari syndrom
achiev diseas control prior system patient random receiv three
mg oral tablet day follow day rest placebo use dose regimen primari
endpoint studi secondari endpoint time symptom worsen outcom measur
includ time progress time next treatment overal respons rate durat respons overal surviv safeti
heath relat qualiti life
domatinostat oral administ select class hdac inhibitor primarili develop
combin treatment inhibitor conduct phase ib/ii studi test domatinostat plu
merck nyse keytruda pembrolizumab melanoma patient progress inhibitor
alon initi data readout expect studi complet inhibit hdac
class may induc sever posit chang tumor microenviron enhanc activ checkpoint
inhibitor preclin studi domatinostat demonstr abil increas number cell
stimul natur killer cell activ enhanc inflammatori signatur increas present tumor
associ class hdac inhibit also associ increas mhc/hla express
increas suscept cancer cell attack follow inhibit importantli domatinostat
inhibit class ii hdac thought immunosuppress effect
investig sponsor phase ii emerg trial plan begin test domatinostat
pfizer/merck kgaa nyse pfe/etr inhibitor bavencio avelumab chemotherapi experienc
checkpoint inhibitor nave patient advanc stage micro-satellit stabl gastrointestin cancer typic
respond checkpoint inhibitor depend data two discuss studi plan begin
pivot trial domatinostat patient relapsed/refractori advanc merkel-cel carcinoma
molecular structur domatinostat shown figur
kohlhof et al epigenet modul pave way checkpoint inhibit journal clinic oncolog
domatinostat previous evalu phase topa trial variou hematolog malign treatment
heavily-pretr patient well toler dlt reach anti-tumor activ
highlight one patient experienc complet respons cr month anoth achiev
partial respons pr month diseas control rate dcr trial although priorit
develop domatinostat solid tumor data provid evid treatment safe anti-
domatinostat mechan action domatinostat select inhibit class hdac evid
specif hdac class import immune-modulatori effect describ make domatinostat potenti
combin partner checkpoint inhibitor addit block hdac activ allow accumul
acetyl histon express previous silenc gene re-activ specif gene cancer cell
result multipl anti-canc effect previous describ
potenti synergi class hdac inhibitor
inhibitor merck nyse keytruda bristol-my squibb nyse opdivo work
block interact also target key immun checkpoint
often prevent cell nk cell tumor associ macrophag recogn attack tumor cell
class therapeut develop immuno-oncolog backbon treatment target axi
keytruda opdivo demonstr activ across wide rang cancer indic includ melanoma
nsclc renal cell carcinoma rcc hepatocellular carcinoma urotheli carcinoma other cumul
sale drug class roughli billion market expect expand therapi
becom cornerston treatment sever cancer respons inhibit vari cancer type although
key predictor respons resist shown figur
figur reason respons loss respons inhibit
predictor respons
high level tumor infiltr
predictor resist
number til
high mutat burden
inabl t-effector lymphocyt
high mhc
level neg immun
regulatori cell tumor
recogn tumor cell
down-regul
high level neg immun
regulatori cell tumor
current develop domatinostat combin treatment inhibitor class hdac
inhibitor possess numer immune-stimulatori properti support explor combin therapi
inhibitor mention class hdac inhibit lead increas number cell
stimul natur killer cell activ enhanc inflammatori signatur increas present tumor
associ antigen also lead up-regul mhc/hla express increas
suscept cancer cell inhibit
sever preclin studi conduct suggest domatinostat potenti enhanc immun
respons cancer discuss preclin studi show treatment domatinostat increas
inflammation-associ molecul cytokin includ associ antigen present
cell infiltr tumor microenviron chang like contribut signific tumor reduct
immun modul effect inflamm marker preclin studi conduct focus
immune-modul effect domatinostat shown figur in-vitro assay demonstr treatment
domatinostat cancer cell line result increas inflammation-associ molecul cytokin
associ tumor associ antigen present hla
figur domatinostat effect express mhc co-stimulatori molecul cancer cell line
treatment domatinostat increas tumor infiltr cell mice in-vivo studi use tumor-
bear mice cell line treat domatinostat combin shown
figur domatinostat alter tumor microenviron signific increas number
infiltr cell mice import tumor infiltr cell corel respons
checkpoint inhibit studi demonstr need compet immun system order hdac
inhibit effect immune-compromis mice treat parallel immune-compet mice show
reduct tumor volum
hermann et al plu break increas efficaci checkpoint inhibit
patient advanc melanoma annal oncolog
activ domatinostat therapi in-vivo mous model studi addit
demonstr addit effect domatinostat pair mice treat either
bid bid domatinostat treatment arm receiv either dose combin
therapi inhibitor alon vehicl figur show combin domatinostat
therapi result greatest tumor volum reduct increas surviv dose depend fashion
figur activ /- therapi mice
competit profil domatinostat hdac inhibitor in-vitro studi compar domatinostat
compet select hdac inhibitor shown figur compar hdac inhibitor domatinostat
neg affect viabil function variou cell subset work follow blockad
attack tumor cell transmembran protein interact receptor cell nk cell
tumor associ macrophag form checkpoint prevent immun cell recogn
attack tumor cell previous describ addit inhibitor enhanc immun respons
cancer led high rate durabl respons note mirati cover
hermann et al plu break increas efficaci checkpoint inhibit
patient advanc melanoma annal oncolog
mocetinostat also inhibit hdac class iv thought deplet immunosuppress cell regulatori
treg cell mdsc down-regul activ checkpoint
figur effect hdac inhibitor viabil function cell substrat
market inform non-respond
although domatinostat initi studi treatment melanoma potenti util combin
treatment checkpoint inhibitor could expand tumor type checkpoint inhibitor becom
import treatment option sever form cancer although effect compar convent therapi mani
patient respond treatment option often limit follow progress broad respons rate
inhibitor approv indic present figur respond progress
repres sizeabl market opportun domatinostat respons rate base
prescrib label publish literatur opdivo keytruda bavencio
mirati rational therapeut promis combin hdac inhibitor immun checkpoint inhibitor
figur respons rate approv indic
unresect metastat melanoma
first-lin nsclc express
chemotherapi keytruda advanc nsclc
relaps progress classic hodgkin lymphoma
hsct
local advanc metastat urotheli carcinoma
unfit cisplatin-chemotherapi
recurr metastat cervic cancer
includ monotherapi combin
combin
market opportun combin agent highlight nektar/bristol-my squibb collabor
due vast-numb patient benefit checkpoint inhibitor great interest
pharmaceut compani investor combin agent highlight collabor
bristol-my squibb announc earli
receptor beta subunit bias agonist preliminari phase i/ii data show
encourag respons rate treatment nave melanoma nsclc treatment nave rcc treatment nave
urotheli carcinoma includ neg tumor importantli notabl increas til
immunosuppress regulatori cell contain tumor peripheri therebi allow immunotherapi
combin maintain durabl effect follow earli data bristol-my squibb enter global
develop commerci collabor nektar term agreement
nektar receiv up-front payment billion cash stock elig receiv
addit billion mileston compani share global profit nektar receiv
develop cost also share two compani evalu combin
opdivo indic tumor type size collabor give indic premium
big pharma will pay novel therapi
domatinostat metastat melanoma
melanoma cancer pigment-produc skin cell known melanocyt gener caus combin
genet risk factor ultraviolet light exposur sun estim new case melanoma
diagnos us patient die diseas addit diagnos
expect eu melanoma make total cancer diagnos account roughli
skin cancer although nearli peopl diseas cure identifi earli surviv
patient grade melanoma patient grade iv diseas grade iv melanoma
make least case diseas
us non-hispan white male histor highest risk melanoma follow non-hispan white
femal sun exposur light skin pigment contribut significantli develop melanoma howev
melanoma possibl type skin area bodi typic receiv sun certain
gene commonli mutat melanoma may specif tie pathogenesi commonli
mutat gene melanoma found case braf encod intracellular protein
protein part broader signal transduct pathway map kinas mapk pathway often alter
treatment melanoma initi treatment melanoma gener involv excis malign tissu sinc
type cancer aggress invad surround tissu extent tissu excis depend
stage cancer found surgeon perform excis tri remov cancer tissu
minim damag surround healthi tissu gener involv level guesswork due need
ensur cancer cell remain boundari set surgeon tend aggress
stage melanoma near cure rate due well surgeri remov full lesion advanc
melanoma difficult treat usual requir substanti amount tissu remov ensur full
extent cancer tissu excis melanoma spread inoper system immunotherapi like
bristol-my squibb opdivo nivolumab /- yervoy ipilimumab merck nyse keytruda
pembrolizumab often use agent also carri substanti cost roughli per year
case patient progress respond inhibitor agent yervoy target therapi
specif cancer-caus mutat chemotherapi drug clinic trial recommend roughli half
melanoma mutat braf gene patient mutat either prescrib braf inhibitor
first-lin treatment follow progress checkpoint inhibitor novarti nyse nv tafinlar dabrafenib
roch vtx rog vx zelboraf vemurafenib array biopharma arri braftovi encorafenib
braf inhibitor approv treatment melanoma often combin mek
inhibitor mekinist trametinib cotel cobimetinib mektovi binimetinib due increas efficaci also note
small number patient receiv oncolyt viru imlyg t-vec although
use may increas preliminari data combin inhibitor encourag
siegel et al cancer statist ca cancer journal clinician
ncnn clinic practic guidelin oncolog melanoma
market inform melanoma patient respond inhibitor
epidemiolog american cancer societi estim peopl us diagnos
melanoma die diseas addit estim case diagnos
annual melanoma patient diagnos stage iv diseas
estim least elig patient prescrib inhibitor make potenti candid
domatinostat surviv rate patient stage melanoma patient
grade iv diseas expect surviv rate improv patient receiv immunotherapi
melanoma patient respond frontlin translat
new patient annual could receiv domatinostat us around
eu also note complet respons rate checkpoint inhibitor melanoma
mani patient initi respond eventu progress
domatinostat gastrointestin tumor
investigator-sponsor phase ii emerg trial plan begin test domatinostat plu
bavencio chemotherapi experienc checkpoint inhibitor nave patient advanc stage micro-satellit stabl
gastrointestin cancer includ colorect gastric esophag cancer result trial provid
import inform regard activ domatinostat tumor type typic unrespons
immunotherapi depict figur inform learn trial differ
melanoma plan merkel cell carcinoma studi rel respons cancer immunotherapi
first data emerg studi expect
figur activ immunotherapi gastrointestin tumor
wolchok et al overal surviv combin nivolumab ipilumumab advanc melanoma new
england journal medicin
domatinostat merkel cell carcinoma
intend use clinic studi melanoma gastrointestin tumor proof-of-concept registr
trial merkel cell carcinoma merkel cell carcinoma mcc aggress form skin cancer form
merkel cell present top layer skin roughli new case estim
diagnos us europ year respect although incid significantli increas due better
detect method peopl reach age risk base data surviv rate
stage iiib iv mcc respect howev expect improv go forward
recent approv pfizer/merck mgaa nyse pfe/etr inhibitor bavencio avelumab
although patient diagnos local cancer treat surgic resect alon roughli
half patient recurr diseas develop metastat mean
roughli newli diagnos patient per year us europ could eventu becom candid
immunotherapi
exact caus mcc unknown condit predominantli occur caucasian
year old key risk factor includ prolong sun exposur weaken immun system infect
merkel cell polyomaviru mcv also predictor cancer found case diseas
typic present fast-grow tumor skin skin color shade red blue purpl
initi asymptomat statu mcc patient often misdiagnos present one studi show
mcc tumor initi rule benign cysts/les studi report clinic misdiagnosi
rate least thu report incid may conserv increas better detect method
rational develop domatinostat mcc mcc form cancer well suit immunotherapi
agent current standard care advanc diseas bavencio inhibitor opdivo
keytruda also shown promis activ condit despit newer treatment close patient
respond initi therapi experi indic almost patient eventu
relaps key mechan immun escap loss mhc class express low number infiltr
cell tumor microenviron associ poor discuss shown
preclin section report treatment domatinostat shown abil increas mhc/hla
express number til predictor respons checkpoint inhibitor thu
domatinostat potenti sensitize/resensit tumor checkpoint inhibit follow progress
mcc treatment paradigm depend stage mcc treatment consist surgeri chemotherapi
immunotherapi radiat treatment cancer spread lymph node surgeri primari form
treatment patient may also receiv radiat therapi cancer spread nearbi lymph node
tumor present skin lymph node remov surgeri follow radiat treatment
chemotherapi also use tri lower risk cancer recurr benefit establish
ritter et al revers epigenet silenc mhc class chain-rel protein improv immun
recognit merkel cell carcinoma natur scientif report
paulson et al transcriptome-wid studi merkel cell carcinoma valid intratumor
lymphocyt invas independ predictor surviv journal clinic oncolog
diseas metastat diseas patient receiv bavencio inhibitor opdivo keytruda
bavencio prefer option metastat mcc approv patient year older
diseas acceler approv base orr dor open-label single-arm studi enrol
patient metastat diseas progress chemotherapi patient prior-lin
therapi prior line shown figur overal respons rate patient
achiev partial respons durat respons rang month
respond patient remain treatment least month remain treatment least
month patient progress treatment limit option base mechanist rational
combin domatinostat bavencio plan test combin registr phase ii trial
figur efficaci bavencio metastat mcc
clinic data discuss domatinostat
complet open-label dose-escal phase studi test domatinostat monotherapi patient
heavili pretreat hematolog malign result show sign anti-tumor activ demonstr
treatment well toler part due immunomodul effect inhibit class hdac
compani pivot development focu domatinostat toward solid tumor combin therapi
checkpoint inhibitor current conduct open-label dose-escal single-arm phase ib/ii
sensit trial evalu domatinostat plu keytruda patient unresect stage iii/iv melanoma patient
refractori non-respond therapi data first patient cohort studi
expect studi complet addit investig sponsor phase ii emerg
trial expect begin test domatinostat inhibitor bavencio chemotherapi experienc
checkpoint inhibitor nave patient advanc stage micro-satellit stabl gastrointestin cancer depend
data two discuss studi plan begin registr direct trial domatinostat patient
refractori advanc merkel-cel carcinoma
prior phase studi advanc hematolog malign
domatinostat previous test open-label single-arm dose-escal phase trial heavili pretreat
patient variou advanc hematolog primari endpoint safeti determin
maximum toler dose determin pharmacokinet profil secondari endpoint includ
overal respons rate orr durat respons dor progress free surviv dose domatinostat
test rang mg mg daili result show treatment well toler dlt formal
reach anti-tumor activ observ one patient experienc complet remiss cr
month anoth patient experienc partial respons month diseas control rate trial
patient sd day achiev sd year
phase ib/ii sensit studi melanoma patient progress therapi
novemb began enrol patient open-label dose-escal single-arm phase ib/ii trial
evalu domatinostat plu keytruda patient unresect stage iii/iv melanoma patient
refractori non-respond three cohort plan enrol patient
test differ dose domatinostat keytruda phase ii portion trial patient receiv
recommend dose domatinostat plu keytruda primari endpoint studi safeti toler
durat respons dor progress free surviv time progress ttp overal surviv os
biomark analys conduct better determin immunolog effect domatinostat patient data
first patient cohort expect studi complet
competit landscap immuno-oncolog drug develop
follow initi approv checkpoint inhibitor field immunotherapi drug develop quickli
grown combin studi on-going checkpoint inhibitor approv
immunotherapi combin treatment involv therapi melanoma renal cell
carcinoma chemotherapi therapi lung cancer sever treatment develop
combin checkpoint inhibitor one interest list figur notabl therapi
administ intratumor inject could limit use invas tumor type
discuss data bristol-my squibb relatlimab syndax entinostat mirati
mocetinostat detail
figur select combin treatment develop
mechan
phase
acquir
multi-tki
class iv
primarili
phase i/iia data present esmo assess bristol-my squibb antibodi relatlimab
opdivo patient melanoma relaps refractori therapi inhibitori
checkpoint similar valid cancer target implic develop
resist inhibit result show overal respons rate evalu patient
although patient express least tumor-associ immun cell within tumor margin
overal respons rate compar less express
patient express tumor cr interestingli express lead better patient
respons base result fact inhibitori checkpoint intrigu potenti
target
term safeti treatment gener well toler similar would expect
inhibit alon treatment relat death report patient discontinu treatment due
entinostat class select hdac inhibitor evalu treatment multipl solid tumor syndax
recent announc data phase ib/ii encor studi comb entinostat keytruda patient
melanoma nsclc progress inhibitor compani present result patient
phase ii portion melanoma studi patient receiv prior inhibitor
also receiv prior yervoy receiv prior braf inhibitor shown figur
patient partial respons treatment confirm stabl diseas occur
figur repres chang baselin tumor size median day median durat
respons month rang
figur chang tumor size baselin entinostat keytruda
agarwala et al efficaci safeti entinostat ent pembrolizumab pembro patient
melanoma progress block antibodi asco
term safeti patient experienc least one treatment-emerg advers event teae
grade greater teae grade greater occur patient includ anemia rash
neutropenia hyponatremia
syndax also report data nsclc patient recent updat result show patient progress
on/aft therapi partial respons treatment combin melanoma
nsclc data suggest class hdac inhibit could activ sever tumor type howev note
earlier report domatinostat appear robust class hdac inhibitor base preclin
earli clinic data could provid competit advantag
mirati mocetinostat mocetinostat spectrum-select class iv hdac inhibitor downregul
immunosuppress cell seen agent may relat class iv inhibit wherea immuno-stimulatori
effect may due class inhibit kol consult spoke expect pan-hdac inhibitor
effect immunotherapi combin class /- class iv hdac due inhibit class ii
hdac type induc immunosuppress effect tumor microenviron mirati report
phase ii data evalu mocetinostat plu astrazeneca nyse azn imfinzi durvalumab patient
nsclc progress inhibitor march evalu patient achiev partial
respons confirm three patient remain studi longest durat
week total patient experienc tumor reduct compani note treatment
well toler mostli grade sever patient far enrol studi
mirati plan provid next updat medic meet later year
preclin develop inhibitor two kinas requir hedgehog/gli signal
treatment may applic basal cell carcinoma hedgehog pathway inhibitor approv
solid tumor select molecular alter basal cell carcinoma common form skin cancer
approxim million peopl us diagnos year form skin cancer treatabl
death occur hedgehog pathway inhibitor erivedg vismodegib roche/genentech
vtx rog vx odomzo sonidegib sun pharma nse sunpharma fda approv patient
advanc target hedgehog signal upstream gli transcript factor cancer stem
cell propos hedgehog signal typic activ downstream gli patient progress
approv therapi limit treatment option follow progress differ
approv agent also inhibit kinas associ gli phase i/ii studi may begin
altaba hedgehof signal gli code stem cell cancer metastas scienc signal
strive optim valu non-cor asset licens deal pharmaceut biotech compani
shown figur candid out-licens could elig futur non-dilut
inhibitor
enzym
de novo
agonist
end grant patent pend patent pertain resminostat
year-end gear toward composition-of-matt key market includ us europ japan
china south korea india russia addit resminostat patent cover formul manufactur
process domatinostat issu patent end gear toward composition-
of-matt key global market composit matter patent provid compani exclus
us region includ china japan singapor australia new zealand also
number grant pend patent early-stag pipelin licens
chief execut offic chairman board
jason loveridg join ceo septemb year intern experi across
europ asia us senior manag posit life scienc compani invest profession
deal privat held publicli trade compani addit substanti transact experi
sale partner biotechnolog asset jason loveridg graduat biochemistri microbiolog
univers new south wale australia hold ph biochemistri univers adelaid
frank hermann strong background clinic research develop medic affair oncolog join
june medic director clinic develop promot cdo octob frank
hermann sever year experi medic affair clinic research recent associ medic
director immuno-oncolog bristol-my squibb time share respons sever success
launch nivolumab antibodi variou tumor indic germani medic monitor
studi director two pan-european clinic trial frank hermann pediatrician train sever year
resident/research associ pediatr oncolog hematolog radiolog univers clinic giessen
marburg earn medic degre johann gutenberg univers mainz
susann danhauser-riedl join manag team april long-stand
experi area hematolog oncolog respons clinic trial
year experi lead posit scientif clinic practic pharmaceut industri
medic affair clinic develop join charg medic affair hematolog
 oncolog product glaxosmithklin clinic develop commerci germani susann
danhauser-riedl start medic educ regensburg univers earn medic degre
technic univers munich
risk invest
consid invest high-risk invest develop stage compani histori
take treatment market current fda approv drug portfolio sever
compani tri target indic cancer treatment pipelin especi crowd
competitor lead program yet gener pivot data limit clinic data date furthermor
earli indic efficaci necessarili translat posit late-stag result compani may
unabl obtain suffici capit fund plan develop program regulatori risk associ
develop drug may receiv fda approv candid despit signific time
financi invest regulatori approv market sell drug guarante drug penetr
market sale may meet expect investor
research analyst denot ac cover report certifi multipl research analyst primarili respons
report research analyst denot ac cover within document individu certifi respect
secur subject compani research analyst cover research view express report accur
reflect person view subject secur subject compani part research
analyst compens directli indirectli relat specif recommend view express research
analyst report
